Qualigen Therapeutics, Inc.
For the period ended Mar 31, 2025. Filed Jul 21, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed Jul 21, 2025
FFR$0.89-1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| For the Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| CASH FLOWS FROM OPERATING ACTIVITIES | ||
| Net loss | $(2,646,172) | $(2,032,751) |
| Adjustments to reconcile loss from continuing operations to net cash used in operating activities: | ||
| Stock-based compensation | 269 | 58,651 |
| Change in fair value of warrant liabilities | (39,225) | 133,300 |
| Provision for credit losses of short-term note receivable | 197,000 | — |
| Accrued interest on short-term note receivable | (110,871) | — |
| Loss on monthly redemptions of convertible debt into common stock | — | 147,197 |
| Accretion of discount on convertible debt | — | 103,653 |
| Loss on issuance of convertible debt | — | 358,279 |
| Gain on change in fair value of derivative liabilities | — | (164,497) |
| Amortization of accrued penalty on notes payable | 73,615 | — |
| Fair value of warrant modification for professional services | — | 9,737 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other assets | 913,454 | 721,451 |
| Accounts payable | (37,330) | (421,649) |
| Accrued expenses and other current liabilities | 59,861 | 303,043 |
| Net cash used in operating activities | (1,589,396) | (783,586) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Issuance of short-term note receivable | (305,000) | — |
| Net cash used in investing activities | (305,000) | — |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from the issuance of convertible notes payable | — | 475,000 |
| Proceeds from issuance of short term debt | 750,000 | — |
| Net cash provided by financing activities - continuing operations | 750,000 | 475,000 |
| Net cash provided by financing activities - discontinued operations | — | — |
| Net cash provided by financing activities | 750,000 | 475,000 |
| Net change in cash and cash equivalents | (1,144,396) | (308,586) |
| Cash and cash equivalents from - beginning of period | 1,174,608 | 401,803 |
| Cash and cash equivalents from - end of period | $30,210 | $93,217 |
| NONCASH FINANCING AND INVESTING ACTIVITIES: | ||
| Monthly redemption of convertible debt into common stock | $— | 546,232 |
| Issuance of common stock for the conversion of Series A-2 preferred shares | $2,893,306 | $— |
| Deemed dividend arising from warrant down-round provision | $— | $60,017 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.